Medicine for treating fatty liver disease
Provided is a pharmaceutical composition for the treatment and/or prevention of fatty liver diseases, particularly non-alcoholic fatty liver diseases, which has an excellent ACC2 selective inhibitory effect and does not accompany side effects such as an increase in plasma triglyceride or a decrease...
Saved in:
Main Authors | , , , |
---|---|
Format | Patent |
Language | Chinese English |
Published |
31.01.2023
|
Subjects | |
Online Access | Get full text |
Cover
Loading…
Summary: | Provided is a pharmaceutical composition for the treatment and/or prevention of fatty liver diseases, particularly non-alcoholic fatty liver diseases, which has an excellent ACC2 selective inhibitory effect and does not accompany side effects such as an increase in plasma triglyceride or a decrease in platelet concentration. A pharmaceutical composition for treating and/or preventing fatty liver diseases, which contains a compound represented by formula (I) or a pharmaceutically acceptable salt thereof: (in the formula, R1 is a haloalkyl group or a non-aromatic carbocyclic group, R2 is a hydrogen atom or halogen, R3 is halogen, ring A is a group represented by formula:-L1-is-O-(CH2)-,-(CH2) 2-, etc. And R5 is an alkyl carbonyl group or a carbamoyl group. ).
本发明提供具有优良ACC2选择性抑制作用,不会伴随血浆甘油三酯上升或血小板浓度的降低等副作用,而用于脂肪性肝病,尤其非酒精性脂肪肝病的治疗和/或预防的药物组合物。一种用于治疗和/或预防脂肪性肝病的药物组合物,其含有式(I)所示的化合物或其药学上可接受的盐,该式(I)如下:(式中,R1为卤烷基或非芳香族碳环式基,R2为氢原子或卤素,R3为卤素,环A为式:所示的基,-L1-为-O-(CH2)-、-(CH2)2-等,R4为烷基或卤烷基,R5为烷基羰基或氨甲酰基。)。 |
---|---|
Bibliography: | Application Number: CN202180035760 |